Leerink Partners reiterates Outperform on Cardinal Health stock

Cardinal Health raised fiscal 2026 non-GAAP EPS guidance to at least $10.00 from $9.65–$9.85 (implying a ~$0.15–$0.35 upside to prior guidance), prompting multiple price-target increases (Leerink $275 reiteration; Evercore $260 from $250; Morgan Stanley $245 from $224; TD Cowen $233 from $225). The stock has returned ~74% over the past year and is trading at $219.40 (market cap $51.63B). Management highlighted strong end-market demand, Specialty volume growth and MSO M&A activity; Chief Accounting Officer Mary Scherer plans to retire in Feb 2027 with a search underway.

Analysis

Cardinal’s mix shift toward higher-margin specialty and niche supply lines creates optionality that is underappreciated by headline-focused models. A sustained mix improvement of even 100–200bps can drive mid-single-digit EPS upside over 12–24 months through higher incremental margins and faster FCF conversion, which in turn reduces the implied payback on recent MSO-style tuck-ins.

Second-order beneficiaries include small-cap suppliers to nuclear and diabetes consumables and logistics providers that win higher-frequency, predictable contract flows; conversely, hospital procurement groups and wholesalers with weaker specialty exposure will face margin pressure and potential customer defections. Watch working-capital elasticity — a shift to specialty often increases receivable duration while reducing inventory churn, creating transient FCF volatility even as underlying operating profitability improves.

Key catalysts and timing: M&A integration read-throughs and contract re-bids will play out over the next 6–18 months, and any governance/stability questions around senior accounting leadership can create discrete volatile windows (near-term hiring announcements through early 2027). Regulatory/IRA-style re-pricing events remain the largest latent downside over a 12–36 month horizon; a single unfavorable large re-contract could compress multiples quickly despite solid unit economics.

The consensus tilt to bullishness looks credible operationally but may be partially priced — upside from further multiple expansion is limited unless flow-through and FCF meet or beat expectations over two consecutive quarters. That makes capital-efficient, time-bound option structures and hedged equity exposure the superior way to capture continued execution while limiting tail risk.

Key Decisions for Investors

• Long CAH equity with disciplined sizing: 6–12 month target +25–30% (if execution persists), hard stop -10% from entry; size at 2–4% NAV to avoid single-name concentration and add protective 6-month puts 8–10% OTM (~cost 1–2% of notional) to cap downside to ~12% total loss.
• Defined-risk options: buy 12-month CAH call spread (buy LEAP; sell nearer-term call to fund ~40–60% of premium). Goal: 2–3x return if shares rise 20–35% within 9–12 months; max loss = premium paid. Use as primary performance lever instead of naked long if funding cost of puts is high.
• Pair trade (execution vs peers): long CAH / short broad distributor basket (e.g., MCK, ABC or a small basket if available) sized to neutralize broader healthcare beta. Target: relative outperformance of ~15–20% over 9–18 months; stop if relative spread widens >10% in 3 months indicating idiosyncratic execution failure.
• Income/volatility play: write 1–3 month covered calls on CAH at ~8–12% OTM to harvest elevated premium after positive news flow. Expected yield 4–8% if neutral to modestly up; unwind if shares gap >12% on material update or guidance change.